Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers
    1.
    发明公开
    Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers 有权
    Chinolin-4-ylderivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker

    公开(公告)号:EP1090917A1

    公开(公告)日:2001-04-11

    申请号:EP00121561.5

    申请日:2000-10-02

    CPC分类号: C07D401/04 C07D401/14

    摘要: The present invention relates to compounds of the general formula
    wherein

    R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen;
    R 2 is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or -NHCH 2 CHROH;
    R 3 is hydrogen or halogen;
    R is hydrogen, lower alkyl or -CH 2 OH;
    n is 1 or 2;
       and to pharmaceutically acceptable acid addition salts thereof.
    Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity in mediating processes underlying development of CNS as well as learning and memory formation.

    摘要翻译: 本发明涉及通式为CHEM的化合物,其中R 1为氢,低级烷基,低级烷氧基,羟基,氨基,硝基,氰基,低级烷基 - 氨基,二低级烷基 - 氨基或卤素; R 2是氢,低级烷基,氨基,吡咯烷-3-醇,吡咯烷-2-基 - 甲醇或-NHCH 2 CHROH; R 3是氢或卤素; R为氢,低级烷基或-CH 2 OH; n为1或2; 和其药学上可接受的酸加成盐。 本发明化合物是NMDA(N-甲基-D-天冬氨酸) - 受体亚型选择性阻断剂,其在调节CNS发育过程中的神经元活性和可塑性方面具有关键作用,以及学习和记忆形成。

    Quinolin-4-yl derivatives
    5.
    发明公开
    Quinolin-4-yl derivatives 有权
    Chinolin -4-基 - 衍生物

    公开(公告)号:EP1088818A1

    公开(公告)日:2001-04-04

    申请号:EP00120890.9

    申请日:2000-09-26

    摘要: The invention relates to compounds of formula
    wherein

    R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen;
    R 2 is phenyl, optionally substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, lower alkyl-amino or di-lower alkyl-amino 2,3 -dihydro-benzofuran-5-yl, chroman-6-yl, naphthalen-2-yl, indan-5-yl, lower alkenyl-phenyl, 5,6,7,8-tetrahydro-naphthalenyl, 2,3-dihydro-isoindol-2-yl, 1,2,3,4-tetrahydro-naphthalenyl, benzofuran-2-yl, benzo[b]thiophen-2-yl, lower alkyl-phenyl, 3,4-dihydro-1H-isoquinolin-2-yl or thiophen-3-yl;
    R 3 and R 4 are independently from each other hydrogen or lower alkyl;
    R 5 is hydrogen, lower alkyl, -CH 2 OH or -CH 2 NR 6 R 7 ;
    R 6 and R 7 are independently from each other hydrogen, lower alkyl, - (CH 2 ) n -phenyl, cycloalkyl, -(CH 2 ) m -morpholinyl or form together with the N-atom a saturated ring with 4-6 C-atoms;
    n is 0-3;
    m is 2 or 3;
    X is -NR 8 - or -O-; or
    X and R 5 are together >N(CH 2 ) 2 -; or
    X and R 3 are together >N(CH 2 ) 3 -; and
    R 8 is hydrogen or lower alkyl;
    and to pharmaceutically acceptable acid addition salts thereof, with the exception of the following compounds

    (6-chloro-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol;
    (6-methyl-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol;
    (6-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; and
    (8-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol, which may be used for the treatment of diseases, which relate to the NMDA receptor specific blockers.

    摘要翻译: 本发明涉及式CHEM的化合物,其中R 1是氢,低级烷基,低级烷氧基,羟基,氨基,硝基,氰基,低级烷基 - 氨基,二 - 低级烷基 - 氨基或卤素; R 2是任选被低级烷基,低级烷氧基,卤素,三氟甲基,氨基,低级烷基 - 氨基或二 - 低级烷基 - 氨基2,3-二氢 - 苯并呋喃-5-基,苯并二氢吡喃-6-基 萘-2-基,茚满-5-基,低级烯基 - 苯基,5,6,7,8-四氢 - 萘基,2,3-二氢 - 异吲哚-2-基, 四氢萘基,苯并呋喃-2-基,苯并噻吩-2-基,低级烷基 - 苯基,3,4-二氢-1H-异喹啉-2-基或噻吩-3-基; R 3和R 4彼此独立地为氢或低级烷基; R 5是氢,低级烷基,-CH 2 OH或-CH 2 NR 6 R 7; R 6和R 7彼此独立地为氢,低级烷基, - (CH 2)n - 苯基,环烷基, - (CH 2)m - 吗啉基或与N-原子一起形成饱和环与4- 6个C原子; n为0-3; m为2或3; X是-NR 8 - 或-O-; 或X和R 5一起为N(CH 2)2 - ; 或X和R 3一起为N(CH 2)3 - ; 和R 8是氢或低级烷基; 和其药学上可接受的酸加成盐,但以下化合物(6-氯-2-苯基-4-喹啉基) - (+) - 2-氨基丁醇; (6-甲基-2-苯基-4-喹啉基) - (+) - 2-氨基丁醇; (6-甲氧基-2-苯基-4-喹啉基) - (+) - 2-氨基丁醇; 和(8-甲氧基-2-苯基-4-喹啉基) - (+) - 2-氨基丁醇,其可用于治疗涉及NMDA受体特异性阻断剂的疾病。

    Triazole and imidazole derivatives
    6.
    发明公开
    Triazole and imidazole derivatives 有权
    Triazolderivate

    公开(公告)号:EP1070708A1

    公开(公告)日:2001-01-24

    申请号:EP00114183.7

    申请日:2000-07-13

    摘要: The present invention relates to compounds of the general formula
    wherein

    R 1 ― R 4 signify independently hydrogen, -CF 3 , -OCF 3 , OCHF 2 , -OCH 2 F, lower alkyl, lower alkoxy, halogen, hydroxy, phenyl, benzyl, amino, nitro, pyrrol-1-yl, lower alkyl-sulfonyl, lower alkyl-sulfanyl, cyano or benzyloxy; or
    R 2 and R 3 may be together ―O-(CH 2 ) 2 -O-, -O-CH 2 -O-, -O-(CH 2 ) 2 -, -(CH 2 ) 3 - or ―CH=CH-CH=CH-;
    X signifies ―N=, -N(R 8 )- or ―CH=;
    Y signifies ―N=, =N-, -N(R 8 )- or ―CH=; wherein one of X or Y has to be nitrogen;
    R 5 signifies the group
    wherein
    R 6 and R 7 signify independently from each other hydrogen, lower alkyl, -C(O)-lower alkyl, hydroxy-lower alkyl, lower alkenyl, -C(O)CH 2 OH or
    R 6 and R 7 may be together with the N-atom ―(CH 2 ) n -, -(CH 2 ) 2 -O-(CH 2 ) 2 -, -CH 2 -CH=CH-CH 2 , -CH 2 -CH[OC(O)CH 3 ]-(CH 2 ) 2 , -CH 2 -CH[NHC(O)CH 3 ]-(CH 2 ) 2 , -O-(CH 2 ) 3 -, -CH 2 -CH(OCH 3 )-(CH 2 ) 2 -, -CH 2 -CH(halogen)-(CH 2 ) 2 -, -(CH 2 ) 2 -CH(O-phenyl)-(CH 2 ) 2 -, -(CH 2 ) 2 -N(CHO)-(CH 2 ) 2 -, -(CH 2 ) 2 -N(COCH 3 )-(CH 2 ) 2 -, -CH 2 -CH(OH)-(CH 2 ) 3 -, -(CH 2 ) 2 -CH(OH)-(CH 2 ) 2 - or -(CH 2 ) 2 -N(benzyl)-CH 2 ) 2 -;
    n signifies 3 to 5; and
    R 8 signifies hydrogen, lower alkyl, lower alkenyl, lower alkinyl, -(CH 2 ) m -O-lower alkyl, -(CH 2 ) m -OH, -(CH 2 ) m -CHF 2 , -(CH 2 ) m -CH 2 F, -(CH 2 ) m -C(O)-lower alkyl, - (CH 2 ) m -C(O)O-lower alkyl, -(CH 2 ) m -CH(OH)-lower alkyl, -(CH 2 ) m -CH(OH)-(CH 2 ) m OH, -(CH 2 ) m -C 6 H 5 , which phenyl ring is optionally substituted by lower alkyl, lower alkoxy or hydroxy, -(CH 2 ) m -C(=CH 2 )-lower alkyl, - (CH 2 ) m -cycloalkyl, -(CH 2 ) m -CN, -(CH 2 ) m -pyridin-4-yl, -(CH 2 ) m -pyridin-3-yl or - (CH 2 ) m -pyridin-2-yl;
    m signifies 0 to 4;
    and to their pharmaceutically acceptable acid addition salts. These compounds may be used for the treatment of diseases related to the NMDA receptor subtype selective blockers.

    摘要翻译: 本发明涉及通式的化合物,其中R 1 -R 4独立地表示氢,-CF 3,-OCF 3,OCHF 2,-OCH 2 F,低级烷基,低级烷氧基,卤素,羟基,苯基, 苄基,氨基,硝基,吡咯-1-基,低级烷基 - 磺酰基,低级烷基 - 硫烷基,氰基或苄氧基; 或R 2和R 3可以一起-O-(CH 2)2 -O - , - O-CH 2 -O-,-O-(CH 2)2 - , - (CH 2)3 - 或-CH = CH-CH = CH-; X表示-N =,-N(R 8) - 或-CH =; Y表示-N =,= N-,-N(R 8) - 或-CH =; 其中X或Y中的一个必须是氮; R 5表示基团,其中R 6和R 7彼此独立地表示氢,低级烷基,-C(O) - 低级烷基,羟基 - 低级烷基,低级烯基,-C( O)CH 2 OH或R 6和R 7可以与N-原子 - (CH 2)n - , - (CH 2)2 -O-(CH 2)2 - , - CH 2 -CH = CH-CH 2 ,-CH 2 -CH(O)CH 3 - (CH 2)2,-CH 2 -CHNC(O)CH 3 - (CH 2)2,-O-(CH 2)3 - , - CH 2 -CH(OCH 3) - )2-,-CH 2 -CH(卤素) - (CH 2)2 - , - (CH 2)2 -CH(O-苯基) - (CH 2)2 - , - (CH 2)2 -N(CHO) - )2-, - (CH 2)2 -N(COCH 3) - (CH 2)2 - , - CH 2 -CH(OH) - (CH 2)3 - , - (CH 2)2 -CH(OH) - (CH 2)2 - 或 - (CH 2)2 -N(苄基)-CH 2)2 - ; n表示3到5; (CH2)m-OH, - (CH2)m-CHF2, - (CH2)m-CH2F, - (CH2)m-CHF2, - (CH 2)m C(O) - 低级烷基, - (CH 2)m C(O)O-低级烷基, - (CH 2)m -CH(OH) - 低级烷基, - (CH 2)m -CH(OH) (CH2)mOH, - (CH2)m-C6H5,该苯基环任选被低级烷基,低级烷氧基或羟基取代, - (CH 2)m C(= CH 2) - 低级烷基, - (CH 2)m - (CH 2)m - 吡啶-3-基或 - (CH 2)m - 吡啶-2-基; - (CH 2)m - m表示0到4; 及其药学上可接受的酸加成盐。 这些化合物可用于治疗与NMDA受体亚型选择性阻断剂有关的疾病。